Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All 12 shareholder proposals approved, preserving governance continuity through the 2027 annual meeting.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All 12 shareholder proposals approved, preserving governance continuity through the 2027 annual meeting
- Board compensation cap set at $2,500,000; executive fixed and variable compensation capped at $2,600,000 and $5,500,000
- Equity incentive plan share authorization increased, expanding potential employee equity dilution
- Capital range increased to CHF 10,378,109.12–CHF 15,567,163.68
- Conditional share capital expanded to 16,836,253 employee shares and 48,026,929 financing, acquisition and other-purpose shares
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.